JP4188837B2 - Ｎｍｄａレセプターリガンドとしてのピリジン誘導体 - Google Patents
Ｎｍｄａレセプターリガンドとしてのピリジン誘導体 Download PDFInfo
- Publication number
- JP4188837B2 JP4188837B2 JP2003542174A JP2003542174A JP4188837B2 JP 4188837 B2 JP4188837 B2 JP 4188837B2 JP 2003542174 A JP2003542174 A JP 2003542174A JP 2003542174 A JP2003542174 A JP 2003542174A JP 4188837 B2 JP4188837 B2 JP 4188837B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- pyridin
- dihydro
- isoquinolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title claims description 9
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title claims description 9
- 239000003446 ligand Substances 0.000 title 1
- 150000003222 pyridines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 151
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 83
- AZKCYSCBPAJCPT-UHFFFAOYSA-N 2-(3,4-dihydro-1h-isoquinolin-2-yl)pyridin-4-amine Chemical compound NC1=CC=NC(N2CC3=CC=CC=C3CC2)=C1 AZKCYSCBPAJCPT-UHFFFAOYSA-N 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 50
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 150000003839 salts Chemical class 0.000 claims description 31
- -1 3,4-dihydro-1H-isoquinolin-2-yl Chemical group 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 11
- 230000004770 neurodegeneration Effects 0.000 claims description 11
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 10
- 208000002193 Pain Diseases 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- RLVQGJIROUBSPL-UHFFFAOYSA-N ethyl 2-[[4-(3,4-dihydro-1h-isoquinolin-2-yl)-6-methylpyridin-2-yl]amino]-2-oxoacetate Chemical compound CC1=NC(NC(=O)C(=O)OCC)=CC(N2CC3=CC=CC=C3CC2)=C1 RLVQGJIROUBSPL-UHFFFAOYSA-N 0.000 claims description 7
- AWSWSDJGJTXACL-UHFFFAOYSA-N 2-(3,4-dihydro-1h-isoquinolin-2-yl)-5-methylpyridin-4-amine Chemical compound C1=C(N)C(C)=CN=C1N1CC2=CC=CC=C2CC1 AWSWSDJGJTXACL-UHFFFAOYSA-N 0.000 claims description 6
- 235000019253 formic acid Nutrition 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- UPWCCXZYHXYHRR-UHFFFAOYSA-N 2-(3,4-dihydro-1h-isoquinolin-2-yl)-6-ethylpyridin-4-amine Chemical compound CCC1=CC(N)=CC(N2CC3=CC=CC=C3CC2)=N1 UPWCCXZYHXYHRR-UHFFFAOYSA-N 0.000 claims description 4
- BHXPHZOOSSXCHR-UHFFFAOYSA-N 2-(3,4-dihydro-1h-isoquinolin-2-yl)-n-methylpyridin-4-amine Chemical compound CNC1=CC=NC(N2CC3=CC=CC=C3CC2)=C1 BHXPHZOOSSXCHR-UHFFFAOYSA-N 0.000 claims description 4
- BWIGAKMTCNFCFE-UHFFFAOYSA-N 2-[[2-(3,4-dihydro-1h-isoquinolin-2-yl)pyridin-4-yl]amino]ethanol Chemical compound OCCNC1=CC=NC(N2CC3=CC=CC=C3CC2)=C1 BWIGAKMTCNFCFE-UHFFFAOYSA-N 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 208000005298 acute pain Diseases 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 150000001721 carbon Chemical group 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- YSDYZWDWFNMKFW-UHFFFAOYSA-N 2-(3,4-dihydro-1h-isoquinolin-2-yl)-6-methylpyridin-4-amine Chemical compound CC1=CC(N)=CC(N2CC3=CC=CC=C3CC2)=N1 YSDYZWDWFNMKFW-UHFFFAOYSA-N 0.000 claims description 3
- RLTYKBNDXIAOJH-UHFFFAOYSA-N 2-(4-methyl-3,4-dihydro-1h-isoquinolin-2-yl)pyridin-4-amine Chemical compound C1C2=CC=CC=C2C(C)CN1C1=CC(N)=CC=N1 RLTYKBNDXIAOJH-UHFFFAOYSA-N 0.000 claims description 3
- SNEWDBZYBSANKX-UHFFFAOYSA-N 4-(3,4-dihydro-1h-isoquinolin-2-yl)pyridin-2-amine Chemical compound C1=NC(N)=CC(N2CC3=CC=CC=C3CC2)=C1 SNEWDBZYBSANKX-UHFFFAOYSA-N 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 230000006726 chronic neurodegeneration Effects 0.000 claims 2
- SOFHJXSQCMUXKH-UHFFFAOYSA-N 2-pyridin-2-yl-3,4-dihydro-1h-isoquinoline Chemical compound C1CC2=CC=CC=C2CN1C1=CC=CC=N1 SOFHJXSQCMUXKH-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 39
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 33
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 32
- 239000000203 mixture Substances 0.000 description 31
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 28
- 239000012458 free base Substances 0.000 description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 25
- 239000012074 organic phase Substances 0.000 description 21
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 239000002178 crystalline material Substances 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000004587 chromatography analysis Methods 0.000 description 14
- 229910004298 SiO 2 Inorganic materials 0.000 description 13
- 239000000460 chlorine Substances 0.000 description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 11
- 238000010626 work up procedure Methods 0.000 description 10
- 239000012280 lithium aluminium hydride Substances 0.000 description 9
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- KZFAWZANSXHSCN-UHFFFAOYSA-N 4-(3,4-dihydro-1h-isoquinolin-2-yl)-6-methylpyridin-2-amine Chemical compound NC1=NC(C)=CC(N2CC3=CC=CC=C3CC2)=C1 KZFAWZANSXHSCN-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- PWRLUVIRGGDEJK-UHFFFAOYSA-N 2-(3,4-dihydro-1h-isoquinolin-2-yl)-n-ethylpyridin-4-amine Chemical compound CCNC1=CC=NC(N2CC3=CC=CC=C3CC2)=C1 PWRLUVIRGGDEJK-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000012230 colorless oil Substances 0.000 description 5
- SYCPILSKZWDGPU-UHFFFAOYSA-N ethyl 2-[[2-(3,4-dihydro-1h-isoquinolin-2-yl)-6-methylpyridin-4-yl]amino]-2-oxoacetate Chemical compound CCOC(=O)C(=O)NC1=CC(C)=NC(N2CC3=CC=CC=C3CC2)=C1 SYCPILSKZWDGPU-UHFFFAOYSA-N 0.000 description 5
- 239000001530 fumaric acid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000003039 volatile agent Substances 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- 0 CCOC(Nc1c(*)c(N2CC(C=CC#*)=C(C)C(*)C2)cc(*)n1)=O Chemical compound CCOC(Nc1c(*)c(N2CC(C=CC#*)=C(C)C(*)C2)cc(*)n1)=O 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
- OWZFULPEVHKEKS-UHFFFAOYSA-N ethyl 2-chloro-2-oxoacetate Chemical compound CCOC(=O)C(Cl)=O OWZFULPEVHKEKS-UHFFFAOYSA-N 0.000 description 4
- 239000008098 formaldehyde solution Substances 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- JHKKCDOQENTIHK-UHFFFAOYSA-N n-[2-(3,4-dihydro-1h-isoquinolin-2-yl)pyridin-4-yl]acetamide Chemical compound CC(=O)NC1=CC=NC(N2CC3=CC=CC=C3CC2)=C1 JHKKCDOQENTIHK-UHFFFAOYSA-N 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- NLCMEPOEDTUKDY-UHFFFAOYSA-N 2-(3,4-dihydro-1h-isoquinolin-2-yl)-n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC(N2CC3=CC=CC=C3CC2)=C1 NLCMEPOEDTUKDY-UHFFFAOYSA-N 0.000 description 3
- CLOBRFOJYSYUJF-UHFFFAOYSA-N 2-[[2-(3,4-dihydro-1h-isoquinolin-2-yl)-5-methylpyridin-4-yl]amino]ethanol Chemical compound C1=C(NCCO)C(C)=CN=C1N1CC2=CC=CC=C2CC1 CLOBRFOJYSYUJF-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- BYSWLMAQOOBBEG-UHFFFAOYSA-N 6-(3,4-dihydro-1h-isoquinolin-2-yl)pyridine-2-carboxamide Chemical compound NC(=O)C1=CC=CC(N2CC3=CC=CC=C3CC2)=N1 BYSWLMAQOOBBEG-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- BCHRZZNYEZLETK-UHFFFAOYSA-N [4-amino-6-(3,4-dihydro-1h-isoquinolin-2-yl)pyridin-2-yl]methanol Chemical compound NC1=CC(CO)=NC(N2CC3=CC=CC=C3CC2)=C1 BCHRZZNYEZLETK-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- QWPGPINFOYVUMR-UHFFFAOYSA-N ethyl 2-[[2-(3,4-dihydro-1h-isoquinolin-2-yl)-5-methylpyridin-4-yl]amino]-2-oxoacetate Chemical compound C1=C(C)C(NC(=O)C(=O)OCC)=CC(N2CC3=CC=CC=C3CC2)=N1 QWPGPINFOYVUMR-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- MNXKPYGCTXTCRR-UHFFFAOYSA-N n-[2-(3,4-dihydro-1h-isoquinolin-2-yl)pyridin-4-yl]benzamide Chemical compound C=1C=NC(N2CC3=CC=CC=C3CC2)=CC=1NC(=O)C1=CC=CC=C1 MNXKPYGCTXTCRR-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- GXMKNEVKXAOLGL-UHFFFAOYSA-N 2-(3,4-dihydro-1h-isoquinolin-2-yl)-5,6,7,8-tetrahydroquinolin-4-amine Chemical compound C1CC2=CC=CC=C2CN1C(C=C1N)=NC2=C1CCCC2 GXMKNEVKXAOLGL-UHFFFAOYSA-N 0.000 description 2
- PDWIXUPKLCRNMD-UHFFFAOYSA-N 2-(3,4-dihydro-1h-isoquinolin-2-yl)pyridin-3-amine Chemical compound NC1=CC=CN=C1N1CC2=CC=CC=C2CC1 PDWIXUPKLCRNMD-UHFFFAOYSA-N 0.000 description 2
- MLZJNABNOIALND-UHFFFAOYSA-N 2-[[2-(3,4-dihydro-1h-isoquinolin-2-yl)-6-methylpyridin-4-yl]amino]ethanol Chemical compound CC1=CC(NCCO)=CC(N2CC3=CC=CC=C3CC2)=N1 MLZJNABNOIALND-UHFFFAOYSA-N 0.000 description 2
- HOPVAQQEEJHKLT-UHFFFAOYSA-N 2-[[4-(3,4-dihydro-1h-isoquinolin-2-yl)-6-methylpyridin-2-yl]amino]ethanol Chemical compound OCCNC1=NC(C)=CC(N2CC3=CC=CC=C3CC2)=C1 HOPVAQQEEJHKLT-UHFFFAOYSA-N 0.000 description 2
- BYNSBDLYGJLWSW-UHFFFAOYSA-N 2-bromo-1-oxido-5,6,7,8-tetrahydroquinolin-1-ium Chemical compound C1CCCC2=C1C=CC(Br)=[N+]2[O-] BYNSBDLYGJLWSW-UHFFFAOYSA-N 0.000 description 2
- XICXWCILIDFKQV-UHFFFAOYSA-N 2-bromo-4-nitro-1-oxido-5,6,7,8-tetrahydroquinolin-1-ium Chemical compound C1CCCC2=C1[N+]([O-])=C(Br)C=C2[N+](=O)[O-] XICXWCILIDFKQV-UHFFFAOYSA-N 0.000 description 2
- CLNAWSBQGFCTHZ-UHFFFAOYSA-N 2-bromo-5,6,7,8-tetrahydroquinolin-4-amine Chemical compound C1CCCC2=C1N=C(Br)C=C2N CLNAWSBQGFCTHZ-UHFFFAOYSA-N 0.000 description 2
- RYMSPPQBKBRUQJ-UHFFFAOYSA-N 2-bromo-6-ethyl-1-oxidopyridin-1-ium Chemical compound CCC1=CC=CC(Br)=[N+]1[O-] RYMSPPQBKBRUQJ-UHFFFAOYSA-N 0.000 description 2
- BVBRVPXLHHOEMP-UHFFFAOYSA-N 2-bromo-6-methyl-4-nitropyridine Chemical compound CC1=CC([N+]([O-])=O)=CC(Br)=N1 BVBRVPXLHHOEMP-UHFFFAOYSA-N 0.000 description 2
- GNTGEMWEXKBWBX-UHFFFAOYSA-N 2-bromopyridin-4-amine Chemical compound NC1=CC=NC(Br)=C1 GNTGEMWEXKBWBX-UHFFFAOYSA-N 0.000 description 2
- BYYGANJGMXVLND-UHFFFAOYSA-N 4-bromo-6-methylpyridin-2-amine Chemical compound CC1=CC(Br)=CC(N)=N1 BYYGANJGMXVLND-UHFFFAOYSA-N 0.000 description 2
- BAQKUNMKVAPWGU-UHFFFAOYSA-N 4-bromopyridin-2-amine Chemical compound NC1=CC(Br)=CC=N1 BAQKUNMKVAPWGU-UHFFFAOYSA-N 0.000 description 2
- VVSDGBZKLNQFRZ-UHFFFAOYSA-N BrC1=CC(=CC(=N1)C(=O)O)[N+](=O)[O-].NC1=CC(=NC(=C1)Br)CO Chemical compound BrC1=CC(=CC(=N1)C(=O)O)[N+](=O)[O-].NC1=CC(=NC(=C1)Br)CO VVSDGBZKLNQFRZ-UHFFFAOYSA-N 0.000 description 2
- UUFOLLXEMAMDKM-UHFFFAOYSA-N BrC1=[N+](C(=CC(=C1)[N+](=O)[O-])CC)[O-].BrC1=NC(=CC(=C1)N)CC Chemical compound BrC1=[N+](C(=CC(=C1)[N+](=O)[O-])CC)[O-].BrC1=NC(=CC(=C1)N)CC UUFOLLXEMAMDKM-UHFFFAOYSA-N 0.000 description 2
- MGGKUGDCARKKPY-UHFFFAOYSA-N BrC1=[N+](C=2CCCCC2C(=C1)[N+](=O)[O-])[O-].BrC1=NC=2CCCCC2C(=C1)N Chemical compound BrC1=[N+](C=2CCCCC2C(=C1)[N+](=O)[O-])[O-].BrC1=NC=2CCCCC2C(=C1)N MGGKUGDCARKKPY-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- QZYPAZSTHJGMGS-UHFFFAOYSA-N ethyl n-[2-(3,4-dihydro-1h-isoquinolin-2-yl)pyridin-4-yl]carbamate Chemical compound CCOC(=O)NC1=CC=NC(N2CC3=CC=CC=C3CC2)=C1 QZYPAZSTHJGMGS-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- DJOSDAVAKRFGJX-UHFFFAOYSA-N n-benzyl-2-(3,4-dihydro-1h-isoquinolin-2-yl)pyridin-4-amine Chemical compound C=1C=NC(N2CC3=CC=CC=C3CC2)=CC=1NCC1=CC=CC=C1 DJOSDAVAKRFGJX-UHFFFAOYSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- QPILYVQSKNWRDD-UHFFFAOYSA-N 1-methyl-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2C(C)NCCC2=C1 QPILYVQSKNWRDD-UHFFFAOYSA-N 0.000 description 1
- YVGPNVIVWQJIAX-UHFFFAOYSA-N 1-methylpyrrolidin-2-one;pyridine Chemical compound C1=CC=NC=C1.CN1CCCC1=O YVGPNVIVWQJIAX-UHFFFAOYSA-N 0.000 description 1
- AKEQXIQPNAIIMS-UHFFFAOYSA-N 2-(2-methylpyridin-4-yl)-3,4-dihydro-1h-isoquinoline Chemical compound C1=NC(C)=CC(N2CC3=CC=CC=C3CC2)=C1 AKEQXIQPNAIIMS-UHFFFAOYSA-N 0.000 description 1
- YYRFNNUNFMRYPC-UHFFFAOYSA-N 2-(4-methylpyridin-2-yl)-3,4-dihydro-1h-isoquinoline Chemical compound CC1=CC=NC(N2CC3=CC=CC=C3CC2)=C1 YYRFNNUNFMRYPC-UHFFFAOYSA-N 0.000 description 1
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
- NZTRUPUDUVCDTC-UHFFFAOYSA-N 2-bromo-5-methylpyridin-4-amine Chemical compound CC1=CN=C(Br)C=C1N NZTRUPUDUVCDTC-UHFFFAOYSA-N 0.000 description 1
- KUENSPFFYCYXPO-UHFFFAOYSA-N 2-bromo-6-ethyl-4-nitro-1-oxidopyridin-1-ium Chemical compound CCC1=CC([N+]([O-])=O)=CC(Br)=[N+]1[O-] KUENSPFFYCYXPO-UHFFFAOYSA-N 0.000 description 1
- TYOSQEKDQKYBLX-UHFFFAOYSA-N 2-bromo-6-ethylpyridine Chemical compound CCC1=CC=CC(Br)=N1 TYOSQEKDQKYBLX-UHFFFAOYSA-N 0.000 description 1
- GKNGDJAGDPAQHO-UHFFFAOYSA-N 2-bromo-6-methylpyridin-4-amine Chemical compound CC1=CC(N)=CC(Br)=N1 GKNGDJAGDPAQHO-UHFFFAOYSA-N 0.000 description 1
- BRUZKHXTJBHXSV-UHFFFAOYSA-N 2-bromopyridin-4-amine;hydrochloride Chemical compound Cl.NC1=CC=NC(Br)=C1 BRUZKHXTJBHXSV-UHFFFAOYSA-N 0.000 description 1
- MANJIGKYCYWWBD-UHFFFAOYSA-N 2-chloro-2-oxoacetic acid Chemical compound OC(=O)C(Cl)=O MANJIGKYCYWWBD-UHFFFAOYSA-N 0.000 description 1
- BSDGZUDFPKIYQG-UHFFFAOYSA-N 4-bromopyridine Chemical compound BrC1=CC=NC=C1 BSDGZUDFPKIYQG-UHFFFAOYSA-N 0.000 description 1
- MPZMVUQGXAOJIK-UHFFFAOYSA-N 4-bromopyridine;hydron;chloride Chemical compound Cl.BrC1=CC=NC=C1 MPZMVUQGXAOJIK-UHFFFAOYSA-N 0.000 description 1
- TWIPIAJYKZMIPL-UHFFFAOYSA-N 4-methyl-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2C(C)CNCC2=C1 TWIPIAJYKZMIPL-UHFFFAOYSA-N 0.000 description 1
- HHEZCTJDFDQBCZ-UHFFFAOYSA-N 4-methyl-2-pyridin-4-yl-3,4-dihydro-1h-isoquinoline Chemical compound C1C2=CC=CC=C2C(C)CN1C1=CC=NC=C1 HHEZCTJDFDQBCZ-UHFFFAOYSA-N 0.000 description 1
- JNYJEGNLNIYAHK-UHFFFAOYSA-N 5-(3,4-dihydro-1h-isoquinolin-2-yl)-1-ethyl-2,4-dihydropyrido[4,3-d][1,3]oxazine Chemical compound C1CC2=CC=CC=C2CN1C1=NC=CC2=C1COCN2CC JNYJEGNLNIYAHK-UHFFFAOYSA-N 0.000 description 1
- YEIHQHJHDWMJOI-UHFFFAOYSA-N 5-(3,4-dihydro-1h-isoquinolin-2-yl)-1-methyl-2,4-dihydropyrido[4,3-d][1,3]oxazine Chemical compound C1CC2=CC=CC=C2CN1C1=NC=CC2=C1COCN2C YEIHQHJHDWMJOI-UHFFFAOYSA-N 0.000 description 1
- OHOZWCJUZQXMAW-UHFFFAOYSA-N 5-chloro-1,2,3,4-tetrahydroisoquinoline Chemical compound C1NCCC2=C1C=CC=C2Cl OHOZWCJUZQXMAW-UHFFFAOYSA-N 0.000 description 1
- MSAAQJGBKBAPHK-UHFFFAOYSA-N 5-chloro-2-pyridin-4-yl-3,4-dihydro-1h-isoquinoline Chemical compound C1CC=2C(Cl)=CC=CC=2CN1C1=CC=NC=C1 MSAAQJGBKBAPHK-UHFFFAOYSA-N 0.000 description 1
- MHQJUEQRWCKJRG-UHFFFAOYSA-N 6-(3,4-dihydro-1h-isoquinolin-2-yl)-4-methylpyridin-2-amine Chemical compound CC1=CC(N)=NC(N2CC3=CC=CC=C3CC2)=C1 MHQJUEQRWCKJRG-UHFFFAOYSA-N 0.000 description 1
- QDOWQPQWJXJCRA-UHFFFAOYSA-N 6-(3,4-dihydro-1h-isoquinolin-2-yl)pyridin-2-amine Chemical compound NC1=CC=CC(N2CC3=CC=CC=C3CC2)=N1 QDOWQPQWJXJCRA-UHFFFAOYSA-N 0.000 description 1
- ABYCTYJDRLQBMT-UHFFFAOYSA-N 6-bromo-4-methylpyridin-2-amine Chemical compound CC1=CC(N)=NC(Br)=C1 ABYCTYJDRLQBMT-UHFFFAOYSA-N 0.000 description 1
- YQBRMUXRAFVSPK-UHFFFAOYSA-N 6-bromo-4-nitropyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC(Br)=N1 YQBRMUXRAFVSPK-UHFFFAOYSA-N 0.000 description 1
- NSURINBXOVVUNR-UHFFFAOYSA-N 6-chloro-1,2,3,4-tetrahydroisoquinoline Chemical compound C1NCCC2=CC(Cl)=CC=C21 NSURINBXOVVUNR-UHFFFAOYSA-N 0.000 description 1
- AHYWGECZZBWYCJ-UHFFFAOYSA-N 6-chloro-2-pyridin-4-yl-3,4-dihydro-1h-isoquinoline Chemical compound C1CC2=CC(Cl)=CC=C2CN1C1=CC=NC=C1 AHYWGECZZBWYCJ-UHFFFAOYSA-N 0.000 description 1
- GIVBFKYXAXLZBT-UHFFFAOYSA-N 6-chloropyridine-2-carboxamide Chemical compound NC(=O)C1=CC=CC(Cl)=N1 GIVBFKYXAXLZBT-UHFFFAOYSA-N 0.000 description 1
- BLRKQLICTKRDDZ-UHFFFAOYSA-N 7-chloro-1,2,3,4-tetrahydroisoquinoline Chemical compound C1CNCC2=CC(Cl)=CC=C21 BLRKQLICTKRDDZ-UHFFFAOYSA-N 0.000 description 1
- PZASAAIJIFDWSB-CKPDSHCKSA-N 8-[(1S)-1-[8-(trifluoromethyl)-7-[4-(trifluoromethyl)cyclohexyl]oxynaphthalen-2-yl]ethyl]-8-azabicyclo[3.2.1]octane-3-carboxylic acid Chemical compound FC(F)(F)C=1C2=CC([C@@H](N3C4CCC3CC(C4)C(O)=O)C)=CC=C2C=CC=1OC1CCC(C(F)(F)F)CC1 PZASAAIJIFDWSB-CKPDSHCKSA-N 0.000 description 1
- HQSAGIBNZOOQQL-UHFFFAOYSA-N 8-chloro-1,2,3,4-tetrahydroisoquinoline Chemical compound C1CNCC2=C1C=CC=C2Cl HQSAGIBNZOOQQL-UHFFFAOYSA-N 0.000 description 1
- AGCMMQLWZZLYDX-UHFFFAOYSA-N 8-chloro-2-pyridin-4-yl-3,4-dihydro-1h-isoquinoline Chemical compound C1C=2C(Cl)=CC=CC=2CCN1C1=CC=NC=C1 AGCMMQLWZZLYDX-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- IPZMPOHKNSLPKU-WLHGVMLRSA-N BrC1=CC(=NC=C1)C.C(\C=C\C(=O)O)(=O)O Chemical compound BrC1=CC(=NC=C1)C.C(\C=C\C(=O)O)(=O)O IPZMPOHKNSLPKU-WLHGVMLRSA-N 0.000 description 1
- SEYFTNKGTHSGJB-UHFFFAOYSA-N BrC1=NC(=CC(=C1)Br)C.BrC1=CC(=NC(=C1)C)N Chemical compound BrC1=NC(=CC(=C1)Br)C.BrC1=CC(=NC(=C1)C)N SEYFTNKGTHSGJB-UHFFFAOYSA-N 0.000 description 1
- ZJIHEKSMHWZFAU-UHFFFAOYSA-N BrC1=NC(=CC=C1)CC.BrC1=[N+](C(=CC=C1)CC)[O-] Chemical compound BrC1=NC(=CC=C1)CC.BrC1=[N+](C(=CC=C1)CC)[O-] ZJIHEKSMHWZFAU-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- SFCLPQGHKDIMPW-UHFFFAOYSA-N ClC1=CC=NC=C1.N1=CC=C(C=C1)N1CC2=CC=CC=C2CC1 Chemical compound ClC1=CC=NC=C1.N1=CC=C(C=C1)N1CC2=CC=CC=C2CC1 SFCLPQGHKDIMPW-UHFFFAOYSA-N 0.000 description 1
- UHNUABZBUDEJJB-UHFFFAOYSA-N ClC1=NC=C(C=C1)[N+](=O)[O-].[N+](=O)([O-])C=1C(=NC=CC1)N1CC2=CC=CC=C2CC1 Chemical compound ClC1=NC=C(C=C1)[N+](=O)[O-].[N+](=O)([O-])C=1C(=NC=CC1)N1CC2=CC=CC=C2CC1 UHNUABZBUDEJJB-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000021617 central nervous system development Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- MKYNHKOAYQRSBD-UHFFFAOYSA-N dioxouranium;nitric acid Chemical compound O=[U]=O.O[N+]([O-])=O.O[N+]([O-])=O MKYNHKOAYQRSBD-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- PAGBUOUYJMWVTQ-UHFFFAOYSA-N ethyl 2-[[2-(3,4-dihydro-1h-isoquinolin-2-yl)pyridin-4-yl]amino]-2-oxoacetate Chemical compound CCOC(=O)C(=O)NC1=CC=NC(N2CC3=CC=CC=C3CC2)=C1 PAGBUOUYJMWVTQ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- FTHUKEBATJXQFL-UHFFFAOYSA-N formic acid;hydrochloride Chemical compound Cl.OC=O FTHUKEBATJXQFL-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- ZDKVEXUAJBZRNH-UHFFFAOYSA-N n-[4-(3,4-dihydro-1h-isoquinolin-2-yl)-6-methylpyridin-2-yl]-2-hydroxyacetamide Chemical compound OCC(=O)NC1=NC(C)=CC(N2CC3=CC=CC=C3CC2)=C1 ZDKVEXUAJBZRNH-UHFFFAOYSA-N 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000007996 neuronal plasticity Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01126467 | 2001-11-09 | ||
| PCT/EP2002/012240 WO2003040128A1 (en) | 2001-11-09 | 2002-11-02 | Pyridine derivatives as nmda receptor ligands |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005513004A JP2005513004A (ja) | 2005-05-12 |
| JP2005513004A5 JP2005513004A5 (enExample) | 2005-12-22 |
| JP4188837B2 true JP4188837B2 (ja) | 2008-12-03 |
Family
ID=8179179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003542174A Expired - Fee Related JP4188837B2 (ja) | 2001-11-09 | 2002-11-02 | Ｎｍｄａレセプターリガンドとしてのピリジン誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6831087B2 (enExample) |
| EP (1) | EP1448547B1 (enExample) |
| JP (1) | JP4188837B2 (enExample) |
| KR (1) | KR100589995B1 (enExample) |
| CN (1) | CN100516061C (enExample) |
| AR (1) | AR037221A1 (enExample) |
| AT (1) | ATE293619T1 (enExample) |
| AU (1) | AU2002351816B8 (enExample) |
| BR (1) | BR0213977A (enExample) |
| CA (1) | CA2467973C (enExample) |
| DE (1) | DE60203820T2 (enExample) |
| ES (1) | ES2240829T3 (enExample) |
| MX (1) | MXPA04004308A (enExample) |
| PL (1) | PL369544A1 (enExample) |
| RU (1) | RU2303037C2 (enExample) |
| WO (1) | WO2003040128A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007008816A (ja) * | 2003-10-15 | 2007-01-18 | Ube Ind Ltd | 新規イソキノリン誘導体 |
| US20050089559A1 (en) * | 2003-10-23 | 2005-04-28 | Istvan Szelenyi | Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
| RU2320654C1 (ru) * | 2006-05-24 | 2008-03-27 | Государственное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ПГФА Росздрава) | 2,2-ДИМЕТИЛ-4-(4,6-ДИМЕТИЛ-2-ПИРИДОН-3-ИЛ)-1,2-ДИГИДРО-БЕНЗО[f]ИЗОХИНОЛИНА ГИДРОХЛОРИД, ПРОЯВЛЯЮЩИЙ ПРЯМОЕ АНТИКОАГУЛЯНТНОЕ ДЕЙСТВИЕ |
| US8722929B2 (en) * | 2006-10-10 | 2014-05-13 | Valeant Pharmaceuticals International | N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators |
| US8367684B2 (en) * | 2007-06-13 | 2013-02-05 | Valeant Pharmaceuticals International | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators |
| US8563566B2 (en) * | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
| US7786146B2 (en) * | 2007-08-13 | 2010-08-31 | Valeant Pharmaceuticals International | Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators |
| EP2065381A1 (de) | 2007-10-18 | 2009-06-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP Antagonisten |
| NZ585347A (en) | 2007-10-18 | 2011-09-30 | Boehringer Ingelheim Int | Cgrp antagonists |
| EP2062889A1 (de) * | 2007-11-22 | 2009-05-27 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verbindungen |
| CA2705405A1 (en) | 2007-11-22 | 2009-05-28 | Boehringer Ingelheim International Gmbh | New compounds |
| CA2705599A1 (en) * | 2007-11-22 | 2009-05-28 | Boehringer Ingelheim International Gmbh | New compounds |
| EA014100B1 (ru) * | 2008-02-21 | 2010-08-30 | Общество С Ограниченной Ответственностью "Валексфарм" | Производные 2,4-диаминопиридина, фармацевтическая композиция, лекарственное средство на их основе для лечения или предупреждения заболеваний и нарушений, вызванных гиперактивацией nmda-рецепторов и/или в качестве стимуляторов когнитивных функций и способ лечения |
| RU2438672C1 (ru) * | 2010-04-30 | 2012-01-10 | Общество с ограниченной ответственностью "Клевер Фарм" | Агент, проявляющий свойства активатора когнитивных функций (варианты) |
| WO2025124571A1 (zh) * | 2023-12-14 | 2025-06-19 | 斯莱普泰(上海)生物医药科技有限公司 | Nmda受体拮抗剂及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9610738B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
| ATE524440T1 (de) * | 1998-05-25 | 2011-09-15 | Abbott Gmbh & Co Kg | Heterocyclische substituierte amide, deren herstellung und anwendung |
| DK1088818T3 (da) | 1999-10-01 | 2005-03-14 | Hoffmann La Roche | Quinolin-4-yl-derivater |
| US6440995B1 (en) * | 1999-10-01 | 2002-08-27 | Hoffman-La Roche Inc. | Quinolin-4-yl derivatives |
| US6339093B1 (en) * | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
-
2002
- 2002-10-29 US US10/282,365 patent/US6831087B2/en not_active Expired - Fee Related
- 2002-11-02 ES ES02787541T patent/ES2240829T3/es not_active Expired - Lifetime
- 2002-11-02 WO PCT/EP2002/012240 patent/WO2003040128A1/en not_active Ceased
- 2002-11-02 PL PL02369544A patent/PL369544A1/xx unknown
- 2002-11-02 KR KR1020047007031A patent/KR100589995B1/ko not_active Expired - Fee Related
- 2002-11-02 CA CA002467973A patent/CA2467973C/en not_active Expired - Fee Related
- 2002-11-02 BR BR0213977-4A patent/BR0213977A/pt not_active IP Right Cessation
- 2002-11-02 AU AU2002351816A patent/AU2002351816B8/en not_active Ceased
- 2002-11-02 JP JP2003542174A patent/JP4188837B2/ja not_active Expired - Fee Related
- 2002-11-02 MX MXPA04004308A patent/MXPA04004308A/es active IP Right Grant
- 2002-11-02 RU RU2004117595/04A patent/RU2303037C2/ru not_active IP Right Cessation
- 2002-11-02 CN CNB028222512A patent/CN100516061C/zh not_active Expired - Fee Related
- 2002-11-02 AT AT02787541T patent/ATE293619T1/de not_active IP Right Cessation
- 2002-11-02 EP EP02787541A patent/EP1448547B1/en not_active Expired - Lifetime
- 2002-11-02 DE DE60203820T patent/DE60203820T2/de not_active Expired - Lifetime
- 2002-11-06 AR ARP020104227A patent/AR037221A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60203820D1 (de) | 2005-05-25 |
| ES2240829T3 (es) | 2005-10-16 |
| KR20050042252A (ko) | 2005-05-06 |
| CN100516061C (zh) | 2009-07-22 |
| EP1448547B1 (en) | 2005-04-20 |
| US6831087B2 (en) | 2004-12-14 |
| CA2467973C (en) | 2009-09-01 |
| RU2303037C2 (ru) | 2007-07-20 |
| MXPA04004308A (es) | 2004-08-11 |
| US20030119870A1 (en) | 2003-06-26 |
| RU2004117595A (ru) | 2006-01-10 |
| BR0213977A (pt) | 2004-08-31 |
| AU2002351816B2 (en) | 2008-03-06 |
| KR100589995B1 (ko) | 2006-06-19 |
| ATE293619T1 (de) | 2005-05-15 |
| CN1585762A (zh) | 2005-02-23 |
| AR037221A1 (es) | 2004-10-27 |
| JP2005513004A (ja) | 2005-05-12 |
| EP1448547A1 (en) | 2004-08-25 |
| PL369544A1 (en) | 2005-05-02 |
| DE60203820T2 (de) | 2006-02-23 |
| AU2002351816B8 (en) | 2008-04-03 |
| WO2003040128A1 (en) | 2003-05-15 |
| CA2467973A1 (en) | 2003-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4188837B2 (ja) | Ｎｍｄａレセプターリガンドとしてのピリジン誘導体 | |
| EP3634958B1 (en) | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists | |
| CN1277604A (zh) | 在烟碱性乙酰胆碱受体上作为胆碱能配体的杂芳基二氮杂环烷类 | |
| TW200306180A (en) | New compounds | |
| SK70899A3 (en) | 6-phenylpyridyl-2-amine derivatives useful as nos inhibitors | |
| WO2012036278A1 (ja) | グリシントランスポーター阻害物質 | |
| AU2002351816A1 (en) | Pyridine Substituted Isoquinoline Derivatives | |
| JP2011225579A (ja) | レニン阻害剤としての３，４−置換ピペリジン誘導体 | |
| CN108017641A (zh) | 吡唑并嘧啶化合物作为pi3k抑制剂及其应用 | |
| KR100591935B1 (ko) | Ｎｍｄａ-수용체 아형 차단제로서의 피리딘 유도체 | |
| CZ20031619A3 (cs) | Deriváty 4-(bifenylkarbonylamino)piperidinu jako inhibitory MTP | |
| KR20220052333A (ko) | 근위축성 측색 경화증 및 관련 장애의 치료를 위한 tdp-43에 결합하는 분자 | |
| NZ579735A (en) | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor | |
| CN115073370A (zh) | 新型烷基氨类化合物或盐、异构体、其制备方法及用途 | |
| NZ251540A (en) | Bridged bis-aryl carbinol derivatives, preparation and medicaments | |
| WO1993019062A1 (en) | Tetrahydropyridine isoxazoline derivatives | |
| JPH09506638A (ja) | アリールおよびヘテロアリールアルコキシナフタレン誘導体 | |
| RU2330020C2 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ АМИНОПИРИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGIuR5 | |
| KR20100119789A (ko) | 2-아미노퀴놀린 | |
| AU2016378154B2 (en) | Phenylimidazole compound | |
| TW200410965A (en) | Compounds | |
| AU2002349396A1 (en) | Pyridine derivatives as NMDA-receptor subtype blockers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080422 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080718 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080909 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080911 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110919 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |